Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

5.6%

10 terminated/withdrawn out of 177 trials

Success Rate

92.6%

+6.1% vs industry average

Late-Stage Pipeline

33%

59 trials in Phase 3/4

Results Transparency

66%

83 of 126 completed trials have results

Key Signals

24 recruiting83 with results7 terminated

Enrollment Performance

Analytics

N/A

59(40.1%)

Phase 3

49(33.3%)

Phase 2

23(15.6%)

Phase 4

10(6.8%)

Phase 1

6(4.1%)

147Total

N/A(59)

Phase 3(49)

Phase 2(23)

Phase 4(10)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (177)

Showing 20 of 177 trials

NCT03334253Phase 3Completed

Low-Dose Atropine for Treatment of Myopia

Role: lead

NCT03146078Active Not Recruiting

Rate of Progression in USH2A-related Retinal Degeneration

Role: lead

NCT07496515Phase 2Not Yet Recruiting

Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia

Role: lead

NCT07599982Not ApplicableRecruiting

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

Role: collaborator

NCT05849753Recruiting

Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes

Role: collaborator

NCT05844982Phase 3Recruiting

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Role: lead

NCT06790784Phase 3Recruiting

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Role: lead

NCT06880835Not ApplicableRecruiting

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

Role: lead

NCT05145491Not ApplicableRecruiting

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

Role: lead

NCT01032603Not ApplicableCompleted

Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia

Role: lead

NCT00320593Phase 3Completed

Correction of Myopia Evaluation Trial 2

Role: lead

NCT02983552Not ApplicableCompleted

Binocular Dig Rush Game Treatment for Amblyopia

Role: lead

NCT02807350Not ApplicableCompleted

Trial of Overminus Spectacle Therapy for Intermittent Exotropia

Role: lead

NCT03263494Phase 3Completed

CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)

Role: lead

NCT05904028Phase 3Active Not Recruiting

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Role: lead

NCT07224321Phase 2Recruiting

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

Role: collaborator

NCT05462821Phase 3Completed

Full-Time Occlusion Therapy for Intermittent Exotropia in Children

Role: lead

NCT07521475Not ApplicableRecruiting

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

Role: collaborator

NCT07676565Recruiting

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

Role: collaborator

NCT06601166Not ApplicableActive Not Recruiting

CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin

Role: collaborator